Product Images Turalio

The text describes a comparison between two treatments, TURALIO and Placebo, with a sample size of 45 and 43 respectively. The table shows the improvement of patients in relation to their baseline in percent, and their tumor response, labeled as either responders or non-responders. The evaluation method is the RECIST (Response Evaluation Criteria in Solid Tumors) v1.1.*

Yuralio (pexidartinib) is a medication that comes in capsule form. Each capsule contains 1359mg of poidarbin hydrochloride and Salvelan 125mg of poidarbin. It is recommended to be taken with a low-fat meal. The trademark of Yuralio belongs to Daichi Sankyo Company, Ltd. The medicine is manufactured by the same company and comes in a pack of 120 capsules. The recommended dosage should be prescribed. Lot 0000 EXP YYYY-AR-DD is the information given for the lot number. The text also includes storage instructions and cautions about keeping it out of reach of children. The rest of the information is illegible.*

Yuralio (pexidartinib) is an oral medication that comes in a capsule form. Each capsule contains 1359 mg of pexidartinib hydrochloride, equivalent to 125 mg of pexidartinib. This medication should be taken with a low-fat meal as directed by a physician. The recommended dosage is on the prescription information. The medication should be stored between 20°C to 25°C (68°F to 77°F) in a closed container with the desiccant undisturbed. It is a registered trademark of Daichi Sankyo Company, Li. The pharmacist should dispense the medication guide to each patient.*